



*General Considerations*




- ◆ 1% of all tumors (considered under-reported)
- ◆ Most common in adults
- ◆ Increased frequency in females with Warthin tumor
- ◆ Fine needle aspiration first line screening test
- ◆ Little known about etiology
- ◆ Site helps separate benign and malignant
- ◆ Clinic stage is important
- ◆ Molecular techniques slow to catch on



*Genetics*

- ◆ Pleomorphic adenoma
  - 8q12 (*PLAG1*) (40%) (increased *PLAG1*)
  - 12q14-15 (*HMGA2*) (8%)
- ◆ Mucoepidermoid carcinoma
  - t(11;19)(q21;p13): *MECT1-MAML2*
  - About 70% of low grade tumors


*Immunohistochemistry*

- ◆ Ductal cell differentiation
  - Keratin (AE1/AE3), CAM5.2, EMA, CEA
- ◆ Myoepithelial cell differentiation
  - Smooth muscle actin, p63, S-100 protein, calponin, GFAP, caldesmon, myosin, MSA
  - Keratin (AE1/AE3), CAM5.2, CK14







Tumor Site Distribution




Tumor Site Distribution  
Minor Salivary Glands Only



Tumor Type Distribution  
MAJOR GLANDS



Tumor Type Distribution  
MINOR GLANDS



*Differential Diagnosis By Anatomic Site*

- ◆ Upper lip
  - Pleomorphic adenoma (mixed tumor)
  - Canalicular adenoma
- ◆ Lower lip
- ◆ Floor of mouth
- ◆ Palate
- ◆ Parotid

*Differential Diagnosis By Anatomic Site*

- ◆ Upper lip
- ◆ Lower lip
  - Mucocele
  - Mucoepidermoid carcinoma
  - Pleomorphic adenoma (mixed tumor)
- ◆ Floor of mouth
- ◆ Palate
- ◆ Parotid

*Differential Diagnosis By Anatomic Site*

- ◆ Upper lip
- ◆ Lower lip
- ◆ Floor of mouth (sublingual & submandibular)
  - Mucoepidermoid carcinoma
  - Adenoid cystic carcinoma
  - Pleomorphic adenoma (mixed tumor)
- ◆ Palate
- ◆ Parotid

*Differential Diagnosis By Anatomic Site*

- ◆ Upper lip
- ◆ Lower lip
- ◆ Floor of mouth
- ◆ Palate
  - Pleomorphic adenoma (mixed tumor)
  - Mucoepidermoid carcinoma
  - Polymorphous low-grade adenocarcinoma
  - Adenoid cystic carcinoma
- ◆ Parotid

*Differential Diagnosis By Anatomic Site*

- ◆ Upper lip
- ◆ Lower lip
- ◆ Floor of mouth
- ◆ Palate
- ◆ Parotid
  - Pleomorphic adenoma (mixed tumor)
  - Warthin tumor
  - Mucoepidermoid carcinoma
  - Acinic cell adenocarcinoma

*Benign versus Malignant*

- ◆ Rate of growth
  - Benign: slow, steady growth (low mitoses)
  - Malignant: rapid increase in size (high mitoses)
    - ✓ Very worrisome if longstanding lesion suddenly develops rapid growth

*Benign versus Malignant*

◆ Relationship with surrounding structures

- Fixation
  - ✓ Benign: Freely movable (palate excluded)
  - ✓ Malignant: Adherent to surrounding tissue
- Ulceration
  - ✓ Benign: Overlying epithelium intact
  - ✓ Malignant: Ulceration of overlying epithelium
- Paresthesia (due to nerve invasion by tumor)
  - ✓ Benign: No change in sensation
  - ✓ Malignant: Paresthesia common




*Benign versus Malignant*



◆ Circumscription

- Benign: Encapsulated; well circumscribed
  - Malignant: Poorly circumscribed; infiltrative
- ... BUT — Be aware of multifocality and minor salivary gland location

*Multifocal, Multilobular, & Without a Capsule*



- ◆ Pleomorphic adenoma
- ◆ Basal cell adenoma
- ◆ Canalicular adenoma
- ◆ Warthin tumor
- ◆ Cystadenomas
- ◆ Oncocytic lesions
  - Oncocytoma vs. nodular hyperplasia






*Benign versus Malignant*

- ◆ Cytological atypia
  - But malignant tumors are frequently bland
  - Profoundly pleomorphic
    - ✓ Salivary duct carcinoma





**WHO histological classification of tumours of the salivary glands**

World Health Organization Tissue Classification	Year	Salivary Gland Neoplasm	Code
Carcinoma ex pleomorphic adenoma			8541/3
Carcinosarcoma			8580/3
Metastasizing pleomorphic adenoma			8540/1
Squamous cell carcinoma			8070/3
Small cell carcinoma			8041/3
Large cell carcinoma			8012/3
Lymphoepithelial carcinoma			8082/3
Sialoblastoma			8574/1
<b>Benign epithelial tumours</b>			
Pleomorphic adenoma			8540/0
Myoepithelioma			8562/0

© 2015 WHO. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior written permission of the publisher, International Agency for Research on Cancer.

*Pleomorphic Adenoma  
Clinical*


- ◆ Most common salivary gland neoplasm
- ◆ Age: 30 – 60 years
- ◆ Sex: F~M
- ◆ Site: Parotid most common site  
75% superficial lobe; 25% deep lobe  
Palate next most common
- ◆ Slow growing, painless, lobular mass  
→ Can reach huge size






*Pleomorphic Adenoma  
Macroscopic*

*Tumor is epithelial (ductal), basal, and myoepithelial with mesenchymal component (myxoid, chondroid, hyaline, osseous)*


- ◆ Tumor may be multinodular
- ◆ Tumor has “pseudopods” that bulge outwards
- ◆ Margins are difficult to assess  
→ Tumor without parotid tissue surrounding it  
→ The capsule may rest on the nerve(s)












*Pleomorphic Adenoma*

- ◆ Remarkably variable histology
  - Solid, tubular, trabecular, cystic
  - Cells literally “melt” into the chondroid or myxoid background stroma
  - Stroma may be heavily fibrotic/hyalinized
  - Spindled, epithelioid, *glandular*, & plasmacytoid cells
  - Squamous metaplasia is common
  - Increased mitotic figures s/p FNA










*Myoepithelioma*

A benign epithelial tumor composed of spindle, plasmacytoid, epithelioid, and clear myoepithelial cells

- ◆ Age: Mean 45 years
- ◆ Sex: Equal
- ◆ Site: Parotid gland and palate
- ◆ Encapsulated


*Myoepithelioma*

- ◆ Similar to PA: **except**
  - **No** myxochondroid matrix
  - **No** ductal elements
- ◆ Plasmacytoid cells in a mucoid stroma and/or interlacing fascicles of spindled cells
- ◆ Immunohistochemistry
  - Positive: CK5/6, p63, SMA, SMMHC, caldesmon, calponin
  - Rare S100 protein positive cells
  - Negative with GFAP



*Immunohistochemistry*

- ◆ Epithelial
  - Keratin, EMA, CK5/6, CK7
- ◆ Myoepithelial
  - Smooth muscle actin, muscle specific actin, p63, GFAP, S-100 protein, calponin
- ◆ Pleomorphic adenoma with 12q chromosomal abnormalities show increased risk of developing carcinoma



p63, EMA, CK5/6

*Pleomorphic Adenoma*

- ◆ Recurrence vs. Recrudescence vs. Residual
- ◆ “Benign” metastasis
- ◆ Malignant transformation can be seen in long standing tumors

*Pleomorphic Adenoma*

**Past Management**

- ◆ Local anaesthetic
- ◆ Direct incision over lump
- ◆ Remove some/any parotid tissue
- ◆ High recurrence rate  
→ 70% Lanier 1972

**Present management**

- ◆ General anaesthesia
- ◆ Remove ALL parotid tissue (superficial and/or deep lobes)
- ◆ <2% recurrence 10 yr

*Carcinoma Ex-Pleomorphic Adenoma*  
*Demographics*

- ◆ About 6-10% of PA develop carcinoma  
→ Represents about 12% of all salivary malignancies  
→ About 4% of all salivary gland tumors
- ◆ Must have pre-existing PA  
→ Only clinical history in some cases  
→ Long history of PA or frequent recurrences  
✓ Risk of 1.5% at 5 years; 10% at 15 years

*Carcinoma Ex-Pleomorphic Adenoma*  
*Clinical*







- ◆ Age: Elderly (usually >60 yrs)
- ◆ Sex: M = F
- ◆ Site: Majority in major glands  
2/3 in parotid
- ◆ Sudden enlargement, with/without nerve symptoms



*Carcinoma Ex-Pleomorphic Adenoma*  
*Pathology*

- ◆ Large tumors  
→ Must have adequate sampling
- ◆ Malignant component adjacent to benign
- ◆ Often poorly differentiated carcinoma  
→ Salivary duct carcinoma common
- ◆ Infiltrative pattern
- ◆ Remarkable cytological atypia
- ◆ Scarring and sclerosis is common  
→ Presence in PA requires additional evaluation





*Carcinoma Ex-Pleomorphic Adenoma*  
*Classification*

- ◆ Subclassified (prognostic significance)
  - Non-invasive = Excellent  
✓ Intracapsular, *in situ*, dysplastic PA
  - Minimally invasive (< 1.5 mm) = Good
  - Invasive (>1.5 mm) = Poor
- ◆ Recurrences (40-50%), usually within 5 yrs
- ◆ Up to 70% show regional and/or distant metastases  
→ Lungs, bone, brain or liver






Ki67



Benign metastasizing pleomorphic adenoma

*Carcinoma Ex-Pleomorphic Adenoma*  
Prognostic Factors


- ◆ Pathologic stage
- ◆ Size
- ◆ Histologic grade and type
- ◆ Proportion of carcinoma
- ◆ Extent of invasion
- ◆ Ki-67 labeling index






*Canalicular adenoma*

*Benign salivary gland neoplasm composed of bilayered strands of basaloid cells that branch and anastomose to form variably sized channels (canaliculi)*

- ◆ Age: >50 years
- ◆ Sex: F > M
- ◆ Site: Predilection for the **upper lip**
- ◆ Minor salivary glands (exclusively)
- ◆ ~20% of are multifocal





*Basal Cell Adenoma  
Demographics*

*Benign epithelial tumor comprised of a relatively uniform, monomorphous proliferation of basaloid cells*

- ◆ Not cell origin—only phenotype
  - Both duct luminal and myoepithelial cells present
- ◆ Don't use "*Monomorphic adenoma*"
- ◆ About 4% of salivary gland tumors
- ◆ Age: peak, 60 years
- ◆ Sex: F > M
- ◆ Site: 80% parotid gland (superficial lateral)  
6% upper lip

*Basal Cell Adenoma  
Clinical*



- ◆ Membranous type basal cell adenomas associated with dermal cylindromas
  - Face and scalp
  - Same molecular alterations at chromosome region 16q12-13
- ◆ Usually single and encapsulated
  - Exception: membranous type is multinodular

*Basal Cell Adenoma  
Histology*

- ◆ Circumscribed and encapsulated
  - Except membranous type
- ◆ Variable number of basal, ductal, and myoepithelial cells, but . . .
- ◆ **Basaloid cells** (not "basal") predominant
- ◆ Monotonous architecture
- ◆ Absence of myxochondroid matrix
- ◆ No spindled and plasmacytoid cells



*Basal Cell Adenoma  
Histology*

- ◆ Small, uniform cuboidal cells with indistinct cell borders, and round to oval nuclei
- ◆ Cytoplasm is usually limited, giving “basophilic” appearance
- ◆ Larger and smaller cells:
  - Larger cells are central
  - Smaller cells cluster at the periphery near stromal interface
- ◆ Palisaded alignment





*Basal Cell Adenoma  
Subtypes*

- ◆ Four subtypes:
  - Solid
    - ✓ Collagenous stroma separates clusters of basaloid epithelial cells
  - Trabecular and tubular
    - ✓ Interlacing, narrow bands of basaloid cells
    - ✓ Palisading of the epithelial nuclei along the stromal interface
  - Membranous
    - ✓ Large quantities of densely collagenous, eosinophilic, PAS positive, hyaline material separate tumor nests
    - ✓ "Jigsaw puzzle"-like
    - ✓ Intracellular droplets may coalesce












*Basal Cell Adenoma  
Immunohistochemistry*

- ◆ Cytokeratin positive
  - Most intense in the duct-luminal cells
- ◆ CEA and EMA positive luminal cells
- ◆ Peripheral cells positive with smooth muscle actin (SMA), myosin, p63 and S100 protein
- ◆ CD117 and bcl-2 are reactive in most tumors





*Basal Cell Adenoma  
Differential Diagnosis*

Criteria	Cellular Pleomorphic Adenoma	Basal cell AdenoCA	Adenoid Cystic Ca
Growth	Encapsulated	Invasive	Invasive
Cribriform pattern	-	-	+++
Cells	Plasmacytoid	Basaloid	Ductal/myoepi.
Stroma relationship	Blending	Abrupt	Surrounded
Mitosis	+	++	+++
Necrosis	-	+	+++
Nuclei	Round	Basal	Angular
Perineural invasion	-	+	+++
Matrix	Myxochondroid	Fibrosis	Reduplicated BM

*Basal Cell Adenoma  
Prognosis and Treatment*

- ◆ Excellent prognosis
- ◆ Surgery with rim of normal tissue
- ◆ Membranous type tends to be multinodular, and associated with a higher recurrence rate (up to 25%)
  - Parotidectomy recommended
- ◆ Malignant transformation may develop
  - Higher for membranous type



*Basal Cell Adenocarcinoma  
Clinical*

*Malignant counterpart of basal cell adenoma showing infiltrative growth*

- ◆ < 1% of all salivary tumors
- ◆ Age: 60 years (mean)
- ◆ Sex: M = F
- ◆ Site: ~90% parotid (superficial lobe)
- ◆ High recurrence rate
  - Up to 40%

*Basal Cell Adenocarcinoma  
Pathology*

- ◆ Invasion/infiltration into salivary gland tissue, soft tissue, nerves and vessels
- ◆ Same patterns and growth as basal cell adenoma
- ◆ Foci of squamous metaplasia
- ◆ Nuclear atypia usually minimal
- ◆ Mitotic index usually low
- ◆ Same immunohistochemistry as basal cell adenoma



*Adenoid Cystic Carcinoma*  
*Demographics*

Malignant epithelial tumor of modified myoepithelial (abluminal) and ductal (luminal) differentiated cells

- ◆ About 5% of all salivary gland tumors
- ◆ 12% of all malignant tumors
- ◆ Age: Peak incidence 6<sup>th</sup> decade
- ◆ Sex: F > M (3:2)
- ◆ Site: Parotid most common site  
Half develop in minor salivary glands  
Most common malignant oral SGT

*Adenoid Cystic Carcinoma*  
*Clinical*

- ◆ Slowly growing swellings or nodules
- ◆ Tenderness, pain, and facial nerve paralysis frequently develop
  - Related to high incidence of nerve invasion
- ◆ Palate tumors frequently have ulceration
- ◆ Small tumors are often mobile
- ◆ Fixation difficult to assess in palate tumors







*Adenoid Cystic Carcinoma*  
*Macroscopic*

- ◆ Poorly circumscribed and unencapsulated
- ◆ Small tumors appear well circumscribed, but this is deceiving
- ◆ Tumors are firm, white to gray-white
- ◆ Multiple frozen section examinations requested due to insidious neural invasion

*Adenoid Cystic Carcinoma*  
*Histology*




*Luminal* ductal cells and *abluminal* modified myoepithelial cells

- ◆ Tracking nerves is a hallmark (peri- or intraneural)
- ◆ “*Encapsulated*” tumors (minor salivary glands) can be difficult to diagnosis
- ◆ Histomorphologically polymorphous but cytomorphologically uniform
- ◆ Myoepithelial-type cells with indistinct cell borders, high N:C ratio with angular, basophilic nuclei



*Adenoid Cystic Carcinoma*  
*Histology*



- ◆ Three major patterns
- ◆ Frequent overlap: use dominant pattern, has prognostic significance:
  - Cribriform
    - ✓ Most common
    - ✓ Punched out, sieve, Swiss cheese-like but in fact ...
    - ✓ Surround, blend and are in direct continuity with pseudocystic structures of basophilic glycosaminoglycans or hyalinized basal lamina material
    - ✓ True glandular lumens lined by cuboidal ductal cells






*Adenoid Cystic Carcinoma  
Histology*

→ Tubular

- ✓ Ductal cells predominate
- ✓ Surrounded by myoepithelial-type cells
- ✓ Separated by stroma, although the continuity is more easily visible in this tumor type
- ✓ Heavily hyalinized stroma may create "stranded" appearance








*Adenoid Cystic Carcinoma  
Histology*

➔ Solid (30% or higher)


- ✓ About 15% of all ACC
- ✓ Lacks stroma
- ✓ Slightly larger cells with less angular nuclei
- ✓ Basaloid myoepithelial cells predominant
- ✓ Increased mitotic figures (5/10 HPFs)
- ✓ Necrosis may be present (pyknosis, apoptosis and comedonecrosis)






*Adenoid Cystic Carcinoma*  
*Immunohistochemistry*


- ◆ Dual population of ductal and myoepithelial cells
- ◆ Ductal cells:
  - More intensely reactive with keratins (pankeratin, CK7, CK19)
  - Variable reactivity with CEA(p) and EMA
- ◆ Abluminal myoepithelial cells:
  - Keratin, vimentin, muscle specific actin, smooth muscle actin, SMMHC, p63, calponin
- ◆ S-100 protein positive
- ◆ CD117 positive (80%)—especially solid variant
  - Not helpful for differential
- ◆ MUC1 positive
- ◆ Limited to absent GFAP




CK5/6



p63



S100 protein



CD117

*Adenoid Cystic Carcinoma  
Grading*

	Grade 1 (45%)	Grade 2 (35%)	Grade 3 (20%)
Circumscription	Good	Deceptive	Never
Necrosis	No	+/-	+
Bone Invasion	No	+/-	+
Perineural invasion*	+/-	+	+++
Dominant pattern	Tubular	Cribriform	Solid
Pleomorphism	+/-	+	++
Mitoses	Rare	Few	Many
Recurrence	50%	80%	100%
15-year survival	39%	26%	5%

*Adenoid Cystic Carcinoma  
Molecular Alterations*

- ◆ About 50% have loss of chromosome 12q12
- ◆ About 30% have translocations between 9p13-23 and 6q
- ◆ LOH at 6q23-25: associated with a poorer prognosis
- ◆ Alteration *p53*: associated with tumor recurrence and progression to solid type

*Adenoid Cystic Carcinoma  
Differential Diagnosis*

- ◆ Cribriform/tubular growth pattern
  - Polymorphous low grade adenocarcinoma:
    - ✓ Exclusively minor salivary gland, "onion-skin", lacks reduplicated basement membrane, cytologically bland with vesicular chromatin
- ◆ Ductal and myoepithelial type cells
  - Pleomorphic adenoma
    - ✓ Lacks invasion, blends with myxochondroid matrix, plasmacytoid cells
  - Epithelial-myoepithelial carcinoma
    - ✓ Biphasic pattern
- ◆ Basaloid pattern
  - Basal cell adenoma, adenocarcinoma, solid variant of adenoid cystic carcinoma

*Adenoid Cystic Carcinoma  
Differential Diagnosis – Basaloid Pattern*

Criteria	Basal cell Adenoma	Basal cell AdenoCA	Solid Adenoid Cystic Ca
Growth	Encapsulated	Invasive	Invasive
Peripheral palisading	+++	++	+/-
Atypia	+	++	+++
Mitosis	+	++	+++
Necrosis	-	+	+++
Squamous areas	+	++	-
Perineural invasion	-	+	+++
Vascular involvement	-	+	+++
Biological behavior	Benign	Low-grade	High-grade

*Adenoid Cystic Carcinoma  
Prognosis and Management*

- ◆ Indolent, but relentless, progressive growth
- ◆ Worse prognosis with increasing clinical stage
  - Tumor size, lymph node metastasis, distant metastasis
  - 10-year survival
    - ✓ Stage I 75%
    - ✓ Stage II 43%
    - ✓ Stage III & IV 15%

*Adenoid Cystic Carcinoma  
Prognosis and Management*

- ◆ Up to 40% occult lymph node metastasis at presentation
- ◆ Late onset of metastases (lungs, bone)
- ◆ Overall survival:
  - 5-year ~80%
  - 10-year ~45%
  - 15-year ~30%



*Adenoid Cystic Carcinoma  
Prognosis and Management*

- ◆Worse outcome (recurrence or prognosis):
  - Solid histologic pattern (15-year: 5%)
  - Higher grade tumors
  - Perineural invasion associated with higher recurrence rate (conflicting results)
  - Sinonasal primaries (worst prognosis)
    - ✓Palate have the best prognosis
  - Increased Ki-67 index (>5-10%)
- ◆Radical surgery is treatment of choice
  - Surgical margin status affects recurrence not overall survival
- ◆Postoperative radiation therapy is commonly used

*Polymorphous Low Grade Adenocarcinoma  
Clinical*

*A malignant epithelial tumor characterized by morphological diversity, cytological uniformity, and a low metastatic potential*

- ◆**PLGA exclusively in minor glands**
- ◆Age: 50-70 years
- ◆Sex: F > M (2:1)
- ◆Site: Palate (60%), junction of hard & soft Upper lip, buccal mucosa, retromolar, and posterior tongue
- ◆Slow growing mass
  - Ulceration, bleeding and pain uncommon







*Polymorphous Low Grade Adenocarcinoma  
Macroscopic*

- ◆2<sup>nd</sup> most common intraoral salivary gland malignancy
- ◆Circumscribed but not encapsulated
- ◆Size:
  - Up to 4 cm
  - Mean: 2 cm
- ◆Firm to solid, ovoid masses
- ◆Close to surface epithelium

*Polymorphous Low Grade Adenocarcinoma  
Microscopic*



- ◆Intact surface
- ◆Prominent “targetoid” perineural infiltration
- ◆Fat invasion
- ◆Normal salivary gland incarcerated by tumor
- ◆Background “slate-grey” myxoid degenerated stromal hyalinization








*Polymorphous Low Grade Adenocarcinoma*  
*Microscopic*

- ◆ Wide variety of patterns
  - Lobules, nests, tubules
  - Linear, single cell (*Indian filing*), concentric targetoid pattern around a nerve
  - Swirling, "Eye-of-the-storm" appearance
- ◆ Cytologically bland
  - Small to medium polygonal cells
  - Abundant pale cytoplasm without distinct border
  - Round nuclei with "vesicular" open nuclear chromatin
  - Mitotic figures are nearly absent





*Polymorphous Low Grade Adenocarcinoma*  
*Immunohistochemistry*

- ◆ Positive:
  - Cytokeratin
  - S100 protein
  - CK5/6
  - p63
  - Glial fibrillary acidic protein (GFAP)
  - Actin
  - bcl-2
  - CD117 (variably positive)

*Polymorphous Low Grade Adenocarcinoma*  
*Differential Diagnosis*

- ◆ Small, incisional biopsy and frozen artifacts make separation difficult
- ◆ Pleomorphic adenoma
  - Circumscribed (but palate tumors are often unencapsulated)
  - Plasmacytoid appearance
  - Chondroid matrix
- ◆ Adenoid cystic carcinoma
  - Destructive growth
  - Smaller cells with hyperchromatic, angular nuclei

*Polymorphous Low Grade Adenocarcinoma*  
*Prognosis and Management*

- ◆ Excellent (>95% 10-year survival)
- ◆ Local recurrence (around 10%)
  - Higher frequency in palate tumor
  - Women develop recurrences more often than men
- ◆ Regional lymph node metastases up to 15%
- ◆ Complete, but conservative surgery
  - May be more extensive due to neural invasion
- ◆ Neck dissection for proven regional metastases